ライフサイエンスコーパス: OAB

1 t to the symptoms associated with IC/BPS and OAB.

2 ration, OAB alone versus no preparation, and OAB versus MBP.

3 ipt of a beta3-agonist or an anticholinergic OAB medication.

4 rescription compared with an anticholinergic OAB prescription.

5 The association between OAB and FD was weak in both groups.

6 The association between OAB and IBS was strong in the control group (OR: 2.42; 9

7 An apparent association between OAB and previous Giardia infection can be ascribed to co

8 CD-based optico-acoustical biosensor (OAB) was used for detection of various types of proteins

9 gic medications to treat overactive bladder (OAB) have been associated with increased risk of cogniti

10 Overactive bladder (OAB) is a highly prevalent symptom complex characterised

11 As overactive bladder (OAB) is a prevalent and chronic medical condition that g

12 Overactive bladder (OAB) is often treated with medications that block the ch

13 Overactive bladder (OAB) symptoms in Parkinson disease (PD) are burdensome,

14 ist for the treatment of overactive bladder (OAB), is described.

15 AR) for the treatment of overactive bladder (OAB).

16 herapy for patients with overactive bladder (OAB); however, this approach is contrary to existing rec

17 Overactive urinary bladder (OAB) negatively impacts quality of life, and stress is k

18 gested that there may be a role for combined OAB and MBP, or OAB alone in the prevention of surgical

19 ticipants included individuals with a filled OAB medication prescription.

20 Treatment modalities for OAB continue to evolve and the abundance of options can

21 I, 64.8-68.2 years) filled prescriptions for OAB medications in 2019; 2 185 214 (73.5%; 95% CI, 62.6%

22 suggests a potentially significant role for OAB preparation, either in combination with MBP or alone

23 the use of long-term antibiotic therapy for OAB seems to be increasing.

24 t of novel non-invasive diagnostic tools for OAB phenotypes that may lead to personalised treatment.

25 mptomatic score group (cluster 1) and a high OAB symptomatic score group (cluster 2).

26 nd gender, in predicting the identified high OAB symptomatic score group was assessed.

27 23.9 [3.1]; behavioral, 24.8 [3.3]) and ICIQ-OAB score (mean [SD], drug, 9.1 [1.7]; behavioral, 8.5 [

28 Incontinence Questionnaire OAB module (ICIQ-OAB) symptom score of 7 or higher (range, 0-16; higher s

29 At 12 weeks postrandomization, ICIQ-OAB scores across groups indicated clinically significan

30 The primary outcome was the 12-week ICIQ-OAB score across groups within a 15% noninferiority marg

31 The underlying pathophysiology of idiopathic OAB is not clearly known and the existence of several ph

32 is noninferior to drug therapy in improving OAB symptoms in PD.

33 her levels of Veillonella and Bacteroides in OAB samples.

34 ly stages of dementia lead to an increase in OAB medication use, rather than the use of OAB medicatio

35 s aimed at restoring a healthy microbiome in OAB patients to mitigate inflammation and improve sympto

36 ptoms and led to the identification of a low OAB symptomatic score group (cluster 1) and a high OAB s

37 entiate between the benefits of combined MBP+OAB or OAB alone.

38 lable on the comparison between combined MBP+OAB versus no preparation, OAB alone versus no preparati

39 The combination of MBP+OAB versus MBP alone was associated with a significant r

40 When a combination of MBP+OAB was compared with OAB alone, no significant differen

41 The method of OAB-detection of proteins is cheap: it requires no speci

42 ight postulate a unique microbial pattern of OAB patients.

43 The prevalence of OAB was 18.7 % (134/716) in the exposed group and 13.6 %

44 ic IBS was associated with increased risk of OAB, whereas post-infectious IBS was not.

45 sults between short-term cognitive safety of OAB anticholinergics and the long-term increased dementi

46 e management of the non-specific syndrome of OAB should follow existing evidence-based investigationa

47 tic therapy and that antibiotic treatment of OAB is not supported by an adequate contemporary evidenc

48 ited efficacy in humans for the treatment of OAB, but development was discontinued due to unacceptabl

49 n OAB medication use, rather than the use of OAB medication causing dementia.

50 e may be a role for combined OAB and MBP, or OAB alone in the prevention of surgical site infection (

51 between the benefits of combined MBP+OAB or OAB alone.

52 tive clinical trials on cognition with other OAB anticholinergics.

53 urthermore, the ability of several potential OAB urinary biomarkers including ATP, ACh, nitrite, MCP-

54 Yet, anticholinergics remain the predominant OAB medication prescribed in the US.

55 ween combined MBP+OAB versus no preparation, OAB alone versus no preparation, and OAB versus MBP.

56 and are incapable of detecting the proposed OAB phenotypes.

57 l Consultation on Incontinence Questionnaire OAB module (ICIQ-OAB) symptom score of 7 or higher (rang

58 going elective colorectal surgery, receiving OAB with or without MBP was performed.

59 s of sacral nerve stimulation for refractory OAB have been recently reported.

60 ction of these heterocyclic ketones with (S)-OAB to obtain enantiomerically pure alcohols, and (3) th

61 ive impairment, the cautious use of selected OAB anticholinergic agents with favourable physicochemic

62 influences of stress, lead to a significant OAB phenotype and reduced bladder capacity.

63 ter stratification by sex, recruitment site, OAB severity, and PD motor symptom severity.

64 me (IC/BPS) and overactive bladder syndrome (OAB) are incompletely understood.

65 e prevalence of overactive bladder syndrome (OAB), and how it was associated with three other functio

66 development of overactive bladder syndrome (OAB).

67 oportion of patients using oxybutynin in the OAB subgroups of the dementia studies, or a study durati

68 We demonstrate the use of the OAB for direct detection of proteins with different mole

69 only in pooled urethral swab samples of the OAB group, but no valid detections were retained in the

70 Combination of the OAB with a mass spectrometer allowed the detection and i

71 dy differs from that of single proteins, the OAB-detection is of particular interest for rapid assay

72 for phenotyping participants based on their OAB characteristic symptoms and led to the identificatio

73 However, the mechanisms linking stress to OAB are not yet fully understood.

74 A prescription for medication to treat OAB.

75 lacebo, but may also have a role in treating OAB symptoms in children and men with lower urinary trac

76 inical chronic inflammation and thus typical OAB symptoms.

77 CF was strongly associated with OAB (OR: 2.73; 95 % CI: 1.85 to 4.02 in the exposed and

78 n a combination of MBP+OAB was compared with OAB alone, no significant difference was seen in SSI or

79 r use of antibiotic therapy in patients with OAB identify few studies - just seven papers and four co

80 ome of the urogenital tract in patients with OAB, leading to subclinical chronic inflammation and thu

81 th myofascial dysfunction from subjects with OAB, IC/BPS, and asymptomatic controls, confirming MUFS

82 ce in the urethral virome between women with OAB and healthy controls.